

Barcelona, 7 October 2026

Ercros showcases its pharmaceutical active ingredients expertise at CPHI Milan

The company has been manufacturing antibiotics since 1945 and has extensive expertise in fermentation technologies, chemical synthesis and sterile manufacturing.

- Ercros offers CDMO (*Contract Development and Manufacturing Organization*) services to the pharmaceutical industry, providing end-to-end solutions in process development, technology transfer, scale-up, industrialisation and the manufacture of active pharmaceutical ingredients (APIs).
- Its portfolio includes fusidic acid, fosfomycins, erythromycins and their derivatives, among other active pharmaceutical ingredients.

Ercros, part of the Bondalti group, is taking part in CPHI Milan from 6 to 8 October, one of the leading international events for the pharmaceutical industry, where it is showcasing its expertise and technological capabilities in the development and manufacture of active pharmaceutical ingredients (APIs).

The company has more than 75 years of experience in this field and has been manufacturing antibiotics since 1945. Its pharmaceutical operations are based at its Aranjuez plant in Madrid, from where it supplies products to pharmaceutical companies in more than 70 countries.

One of Ercros's main strengths is the technological know-how it has built up over the years. The company has industrial fermentation capabilities ranging from laboratory to commercial scale, as well as downstream processing capabilities including purification, filtration, chromatography and drying, as well as chemical synthesis and sterile manufacturing, forming an integrated CDMO offering for the pharmaceutical industry.

Ercros also has a broad portfolio of active pharmaceutical ingredients, including fusidic acid and sodium fusidate; several types of fosfomycins and erythromycins; derivatives of the latter such as azithromycin and clarithromycin; as well as famotidine and amlodipine besylate.

Its presence at CPHI Milan allows Ercros to showcase both its current offering and its capabilities to collaborate with other pharmaceutical companies in the development, transfer and industrialisation of new processes and products.

Ercros will be present at CPHI Milan from 6 to 8 October in Hall 3, Stand C49. [Click here](#) for more information about our participation in the trade fair.

Barcelona, 7 October 2026

About Ercros

Ercros is an industrial group focused on the manufacture and sale of chemical and pharmaceutical products. The principles guiding its activities are the safety of its facilities and the health of people, respect for the environment, product quality, and dialogue and transparency with society.

The company operates across three business areas: the chlorine derivatives division, a strategic unit centred on chlorine; the intermediate chemicals division, focused on formaldehyde chemistry; and the pharmaceuticals division, dedicated to manufacturing active pharmaceutical ingredients. It has 10 production facilities employing approximately 1,350 people and exports nearly half of its output to around 90 countries worldwide.

Since 2026, Ercros is part of Bondalti, a leading company in the Iberian chemical sector belonging to the José de Mello Group.

For further information, please visit ercros.es or follow us on [LinkedIn](#).

Press contact:

Irene Montes | imontes@kreab.com | +34 604 00 63 09